These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254 [TBL] [Abstract][Full Text] [Related]
8. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E; World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261 [TBL] [Abstract][Full Text] [Related]
9. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma. Zennami K; Sumitomo M; Takahara K; Nukaya T; Takenaka M; Fukaya K; Ichino M; Fukami N; Sasaki H; Kusaka M; Shiroki R BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105 [TBL] [Abstract][Full Text] [Related]
10. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. Peyronnet B; Seisen T; Dominguez-Escrig JL; Bruins HM; Yuan CY; Lam T; Maclennan S; N'dow J; Babjuk M; Comperat E; Zigeuner R; Sylvester RJ; Burger M; Mostafid H; van Rhijn BWG; Gontero P; Palou J; Shariat SF; Roupret M Eur Urol Focus; 2019 Mar; 5(2):205-223. PubMed ID: 29154042 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847 [TBL] [Abstract][Full Text] [Related]
12. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis. Kim DK; Lee JY; Kim JW; Hah YS; Cho KS Crit Rev Oncol Hematol; 2019 Mar; 135():59-65. PubMed ID: 30819447 [TBL] [Abstract][Full Text] [Related]
13. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer. Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146 [TBL] [Abstract][Full Text] [Related]
15. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Necchi A; Martini A; Raggi D; Cucchiara V; Colecchia M; Lucianò R; Villa L; Mazzone E; Basile G; Scuderi S; Pederzoli F; Bandini M; Barletta F; Larcher A; Capitanio U; Salonia A; Briganti A; Ross JS; Messina A; Montorsi F Urol Oncol; 2022 Jan; 40(1):10.e1-10.e6. PubMed ID: 34147313 [TBL] [Abstract][Full Text] [Related]
16. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. Pradere B; D'Andrea D; Schuettfort VM; Foerster B; Quhal F; Mori K; Abufaraj M; Margulis V; Deuker M; Briganti A; Muilwijk T; Hendricksen K; Lotan Y; Karakiewic P; F Shariat S; World J Urol; 2021 Jul; 39(7):2567-2577. PubMed ID: 33067726 [TBL] [Abstract][Full Text] [Related]
17. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680 [TBL] [Abstract][Full Text] [Related]
19. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Adibi M; McCormick B; Economides MP; Petros F; Xiao L; Guo C; Shah A; Kamat AM; Dinney C; Navai N; Gao J; Siefker-Radtke A; Matin SF; Campbell MT Clin Genitourin Cancer; 2022 Apr; 20(2):176-182. PubMed ID: 35039231 [TBL] [Abstract][Full Text] [Related]
20. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs. Del Giudice F; van Uem S; Li S; Vilson FL; Sciarra A; Salciccia S; Busetto GM; Maggi M; Tiberia L; Viscuso P; Canale V; Panebianco V; Pecoraro M; Ferro M; Moschini M; Krajewski W; D'Andrea D; Cacciamani GE; Mari A; Soria F; Porpiglia F; Fiori C; Amparore D; Checcucci E; Autorino R; De Berardinis E; Chung BI Clin Genitourin Cancer; 2022 Apr; 20(2):198.e1-198.e9. PubMed ID: 35031226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]